CONTENTS:
- Glucagon-like peptide-1 receptor agonists in alcohol use disorder: Multi-system effects, early clinical promise and uncertain long-term use [Editorial]. Haass-Koffler C.L., p. 1033-1035.
- Zero tolerance for 0%? How should clinicians and other practitioners respond to the use of alcohol-free and low-alcohol products in higher risk groups [Addiction opinion and debate]. Holmes J., Oldroyd C.K., Drummond C., Field M., Kersbergen I., Allison M.E.D., p. 1036-1041.
- Could alcohol-free and low-alcohol beverages be used to extinguish alcohol cravings? Bowdring M.A., p. 1042-1043.
- Seeing through a glass darkly. Sinclair J.M.A., p. 1044-1045.
- Examining definitions and cues associated with alcohol-free and low-alcohol drinks. Holmes J., Field M., Drummond C., p. 1046-1047.
- A meta-analysis of sexual orientation inequities in substance use among youth. Mereish E.H., Lee H., Goldbach J.T., Hathaway S., Hennessy E.A., p. 1048-1063.
- Commentary on Mereish et al.: Supporting sexually diverse youth requires a full spectrum understanding of substance use. London-Nadeau K., Rioux C., p. 1064-1065.
- Buprenorphine-based treatments outcomes in pregnant opioid-dependent women: A systematic review and meta-analysis. Akbarzadeh F., Ebrahimi A., p. 1066-1082.
- Pharmacological treatment strategies to manage precipitated withdrawal following the administration of buprenorphine in opioid use disorder: A systematic review. Roberts E., Kalk N., Strang J., p. 1083-1099.
- Patterns, reasons and characteristics of e-cigarette use in Australia: Findings from the 2022-2023 National Drug Strategy Household Survey. Lim C.C.W., Sun T., Lai G., Hall W., Connor J., Lee Y.Y., et al., p. 1100-1109.
- Commentary on Lim et al.: Real-world e-cigarette use under prescription-only regulation. Kale D., Jackson S., p. 1110-1111.
- Effectiveness of smoking cessation pharmacotherapies during pregnancy: A multi-national population-based study. Robijn A.L., Donald S., Cohen J.M., Tran D.T., Cesta C.E., Furu K., et al., p. 1112-1127.
- Smoking and drinking among the Gypsy and Traveller communities: A population study in England. Taylor E., Tattan-Birch H., Oldham M., East K., Walsh H., Jackson S., p. 1128-1139.
- Appetitive responses toward smoking-related stimuli in abstinence-motivated, non-deprived individuals with chronic tobacco dependence: A multi-methodological investigation. Motka F., Tan H., Levine S.M., Vollstädt-Klein S., Danböck S.K., Bertsch K., et al., p. 1140-1152.
- Trajectories of genetic risk across dimensions of alcohol use behaviors. Savage J.E., Aliev F., Barr P.B., Choi M., Drouard G., Cooke M.E., et al., p. 1153-1165.
- The correlation between sanction adjustments and drunk-driving violations and related outcomes in Taiwan: A nationwide interrupted time series analysis. Kuo L.W., Liao C.A., Cheng C.T., Liao C.H., Hsu C.P., Fu C.Y., et al., p. 1166-1178.
- Endocannabinoid system gene expression in mesocorticolimbic brain regions of individuals with alcohol use disorder: A descriptive study. Garcia-Gutierrez M.S., Torregrosa A.B., Navarrete F., Aracil-Fernandez A., Rubio G., Manzanares J., p. 1179-1189.
- Alcohol use disorder and risk of incident COVID-19 infection: A nested case-control study in Taiwan. Yen Y.F., Lai Y.J., Su S.S., Kuo C.J., p. 1190-1198.
- Comparing the accuracy of artificial intelligence models to detect alcohol in video images. Pararath Salim S., He Z., Millward J., Kuntsche E., Riordan B., p. 1199-1206.
- The impact of opioid, cannabis and cocaine use disorder on the risk of diabetic retinopathy in patients with type 2 diabetes mellitus. Yueh M.P., Yu Y.T., Yeh C.Y., Cheng K.W., Kao S.K., p. 1207-1216.
- The association of methadone use with physical function and frailty among persons who inject drugs. Kulik G.L., Hsu H.Y., Rudolph J., Jiang Y., Erlandson K.M., Piggott D.A., et al., p. 1217-1226.
- Clinical factors linked to xylazine exposure in emergency department patients with illicit opioid overdose. Love J.S., Vargas-Torres C., Aldy K., Brent J., Wax P., Culbreth R., et al., p. 1227-1236.
- Predictors of outpatient treatment engagement following a visit to a specialized emergency department for substance use: A cohort study using high-resolution electronic health records. Romero D., Kaberg M., Berman A.H., Carlbring P., Franck J., Lindner P., p. 1237-1248.
- Is toke cheap? Correspondence between cannabis demand and purchase in the laboratory. Aston E.R., Berey B.L., Amlung M., Swift R., MacKillop J., Metrik J., p. 1249-1261.
- Authorization of storefront recreational cannabis retailers and cannabis-related healthcare encounters: A local-level spatial difference-in-differences analysis in California, United States. Han B., Gunadi C., Shi Y., p. 1262-1271.
- A cost-benefit analysis of the implementation and scale-up of harm reduction interventions in the Australian Capital Territory. Bowring A.L., Tidhar T., Olsen A., Bailie C., Burke K., Martin-Hughes R., et al., p. 1272-1289.
- Trends in gamma-hydroxybutyrate use, harms and treatment in Australia, 2013 to 2024. Peacock A., Chrzanowska A., Man N., Darke S., Brown J., Grigg J., et al., p. 1290-1305.
- Analysing police diversion for simple possession as a policy idea. Ritter A., Kelaita P., p. 1306-1315.
- Addiction-related problems in Japan: A regional perspective. Ide S., Nishitani Y., Sumitani M., Minami M., Isa T., Iseki M., et al., p. 1316-1324.
- Atipamezole merits investigation for use in human α-2 agonist toxicity. Blumenberg A., Murphy L., p. 1325-1326.
- Distinguishing chronic disease profiles and cause of death attribution in opioid and or stimulant toxicity deaths to inform overdose prevention efforts. Palis H., Vincent J., Budau J., Hu K., Tu A., p. 1327-1328.